Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Qinghao, also known as Qinghao Biejia decoction, is a traditional Chinese medicine (TCM) herbal formula. It originates from the classic TCM text "Wenbing Tiaobian" and is primarily used for the treatment of systemic lupus erythematosus (SLE), especially in patients with yin deficiency syndrome. The formula contains multiple herbal ingredients, with *Qinghao* (Artemisia annua or sweet wormwood) as a key component. Artemisinin, an active compound derived from *Qinghao*, has demonstrated anti-inflammatory and immunomodulatory effects relevant to SLE management. Other components contribute additional anti-inflammatory and immune-regulating properties. The mechanism of action includes inhibition of Th17 cell expression and IL-17 production, reduction of inflammation, improvement in immunity, and amelioration of renal pathology associated with SLE[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Compound Qinghao.